Form 4: Charles River Laboratories Director Kochevar Acquires Shares and Stock Options

Director Deborah Turner Kochevar reports acquisition of common stock and stock options in Charles River Laboratories.

Summary

• On May 13, 2024, Deborah Turner Kochevar, a director of Charles River Laboratories International, Inc., acquired 559 shares of common stock at a price of $228.41 per share.
• Following this transaction, Kochevar directly owns 7,894 shares of common stock.
• Kochevar also acquired 1,311 stock options with an exercise price of $228.41, which become exercisable on the earlier of May 13, 2025, or the business day prior to the company's next annual meeting of shareholders.
• These options expire on May 13, 2034.
• The unvested restricted stock units vest upon the earlier of 5/13/2025 or the business day prior to the Company's next annual meeting of shareholders.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The director's acquisition of shares and options suggests confidence, but it's a single transaction and doesn't provide a comprehensive view of the company's overall health.

Positives

• The acquisition of shares and stock options by a director may signal confidence in the company's future performance.

Industry Context

Insider transactions are closely monitored as they can provide insights into a company's prospects. Acquisitions by directors are often seen as a positive sign.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates